| Literature DB >> 27275486 |
Panagiota Economopoulou1, Christos Perisanidis1, Evaggelos I Giotakis1, Amanda Psyrri1.
Abstract
Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low survival rates for advanced stage tumors and minimal improvement in survival trends through the past decades. It is becoming increasingly clear that HNSCC oncogenesis and evolution is characterized by profound immune defects, as cancer cells evade immunosurveillance due to accumulation of genetic mutations and tumor heterogeneity. Improved understanding of the role of the immune system in cancer has led to the identification of novel therapeutic targets, which are being investigated for their potential to provide durable responses. In this review, we will summarize the role of the immune system in HNSCC, the rationale behind immunotherapy strategies and their clinical applications.Entities:
Keywords: Checkpoint inhibitors; head and neck cancer; immune system; immunotherapy
Year: 2016 PMID: 27275486 PMCID: PMC4876265 DOI: 10.21037/atm.2016.03.34
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839